S&P 500   3,750.77 (-2.57%)
DOW   30,303.17 (-2.05%)
QQQ   319.43 (-2.79%)
AAPL   142.06 (-0.77%)
MSFT   232.90 (+0.25%)
FB   272.14 (-3.51%)
GOOGL   1,818.94 (-4.67%)
AMZN   3,232.58 (-2.81%)
TSLA   864.16 (-2.14%)
NVDA   516.71 (-3.85%)
BABA   260.25 (-2.13%)
CGC   37.83 (+6.50%)
GE   11.38 (+0.80%)
MU   75.09 (-5.56%)
AMD   88.84 (-6.20%)
NIO   57.15 (-5.24%)
T   29.14 (-2.05%)
F   10.79 (-3.57%)
ACB   11.20 (+4.97%)
BA   194.03 (-3.97%)
DIS   163.03 (-3.85%)
NFLX   523.28 (-6.88%)
GILD   65.48 (-1.83%)
S&P 500   3,750.77 (-2.57%)
DOW   30,303.17 (-2.05%)
QQQ   319.43 (-2.79%)
AAPL   142.06 (-0.77%)
MSFT   232.90 (+0.25%)
FB   272.14 (-3.51%)
GOOGL   1,818.94 (-4.67%)
AMZN   3,232.58 (-2.81%)
TSLA   864.16 (-2.14%)
NVDA   516.71 (-3.85%)
BABA   260.25 (-2.13%)
CGC   37.83 (+6.50%)
GE   11.38 (+0.80%)
MU   75.09 (-5.56%)
AMD   88.84 (-6.20%)
NIO   57.15 (-5.24%)
T   29.14 (-2.05%)
F   10.79 (-3.57%)
ACB   11.20 (+4.97%)
BA   194.03 (-3.97%)
DIS   163.03 (-3.85%)
NFLX   523.28 (-6.88%)
GILD   65.48 (-1.83%)
S&P 500   3,750.77 (-2.57%)
DOW   30,303.17 (-2.05%)
QQQ   319.43 (-2.79%)
AAPL   142.06 (-0.77%)
MSFT   232.90 (+0.25%)
FB   272.14 (-3.51%)
GOOGL   1,818.94 (-4.67%)
AMZN   3,232.58 (-2.81%)
TSLA   864.16 (-2.14%)
NVDA   516.71 (-3.85%)
BABA   260.25 (-2.13%)
CGC   37.83 (+6.50%)
GE   11.38 (+0.80%)
MU   75.09 (-5.56%)
AMD   88.84 (-6.20%)
NIO   57.15 (-5.24%)
T   29.14 (-2.05%)
F   10.79 (-3.57%)
ACB   11.20 (+4.97%)
BA   194.03 (-3.97%)
DIS   163.03 (-3.85%)
NFLX   523.28 (-6.88%)
GILD   65.48 (-1.83%)
S&P 500   3,750.77 (-2.57%)
DOW   30,303.17 (-2.05%)
QQQ   319.43 (-2.79%)
AAPL   142.06 (-0.77%)
MSFT   232.90 (+0.25%)
FB   272.14 (-3.51%)
GOOGL   1,818.94 (-4.67%)
AMZN   3,232.58 (-2.81%)
TSLA   864.16 (-2.14%)
NVDA   516.71 (-3.85%)
BABA   260.25 (-2.13%)
CGC   37.83 (+6.50%)
GE   11.38 (+0.80%)
MU   75.09 (-5.56%)
AMD   88.84 (-6.20%)
NIO   57.15 (-5.24%)
T   29.14 (-2.05%)
F   10.79 (-3.57%)
ACB   11.20 (+4.97%)
BA   194.03 (-3.97%)
DIS   163.03 (-3.85%)
NFLX   523.28 (-6.88%)
GILD   65.48 (-1.83%)
Log in
NASDAQ:SGEN

Seagen Stock Forecast, Price & News

$162.69
-9.95 (-5.76 %)
(As of 01/27/2021 05:04 PM ET)
Add
Compare
Today's Range
$162.40
Now: $162.69
$170.39
50-Day Range
$166.75
MA: $185.21
$201.15
52-Week Range
$90.57
Now: $162.69
$213.94
Volume1.22 million shs
Average Volume996,076 shs
Market Capitalization$29.43 billion
P/E Ratio64.05
Dividend YieldN/A
Beta1.11
Seagen Inc., a biotechnology company, develops and commercializes therapies for the treatment of cancer in the United States and internationally. The company markets ADCETRIS, an antibody-drug conjugate (ADC) for the treatment of patients with Hodgkin lymphoma or CD30-positive T-cell lymphomas; and PADCEV, an ADC composed of an anti-Nectin-4 monoclonal antibody for the treatment of metastatic urothelial cancers. It also develops Tucatinib, an investigational oral, small molecule TKI for HER2, a growth factor receptor; and Tisotumab Vedotin, an ADC composed of a human antibody that binds to tissue factor to treat various solid tumors, including cervical, ovarian, prostate, and bladder. In addition, the company develops ladiratuzumab vedotin, an ADC targeting LIV-1 and metastatic triple-negative breast cancer; SEA-BCMA, a clinical-stage non-fucosylated BCMA-directed antibody for patients with relapsed or refractory multiple myeloma. Seagen Inc. has collaboration agreements with Takeda Pharmaceutical Company Limited; Agensys, Inc.; Genmab A/S; biotechnology and pharmaceutical companies; and Merck. The company was formerly known as Seattle Genetics, Inc. and changed its name to Seagen Inc. in October 2020. Seagen Inc. was incorporated in 1997 and is headquartered in Bothell, Washington.
Seagen logo

MarketRank

Overall MarketRank

1.30 out of 5 stars

Medical Sector

691st out of 1,926 stocks

Biological Products, Except Diagnostic Industry

95th out of 177 stocks

Analyst Opinion: 2.4Community Rank: 2.5Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.0 5 -4 -3 -2 -1 -

Industry, Sector and Symbol

Industry Biological products, except diagnostic
Sub-IndustryBiotechnology
SectorMedical
Current SymbolNASDAQ:SGEN
CUSIP81257810
Phone425-527-4000
Employees1,605
Year FoundedN/A

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$916.71 million
Book Value$10.95 per share

Profitability

Net Income$-158,650,000.00

Miscellaneous

Market Cap$29.43 billion
Next Earnings Date2/11/2021 (Confirmed)
OptionableOptionable
$162.69
-9.95 (-5.76 %)
(As of 01/27/2021 05:04 PM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive SGEN News and Ratings via Email

Sign-up to receive the latest news and ratings for SGEN and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Seagen (NASDAQ:SGEN) Frequently Asked Questions

How has Seagen's stock been impacted by Coronavirus?

Seagen's stock was trading at $104.51 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, SGEN shares have increased by 55.6% and is now trading at $162.58.
View which stocks have been most impacted by COVID-19
.

Is Seagen a buy right now?

17 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Seagen in the last year. There are currently 1 sell rating, 4 hold ratings, 11 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" Seagen stock.
View analyst ratings for Seagen
or view MarketBeat's top 5 stock picks.

What stocks does MarketBeat like better than Seagen?

Wall Street analysts have given Seagen a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Seagen wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

What is Clay B. Siegall's approval rating as Seagen's CEO?

107 employees have rated Seagen CEO Clay B. Siegall on Glassdoor.com. Clay B. Siegall has an approval rating of 99% among Seagen's employees. This puts Clay B. Siegall in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

When is Seagen's next earnings date?

Seagen is scheduled to release its next quarterly earnings announcement on Thursday, February 11th 2021.
View our earnings forecast for Seagen
.

How can I listen to Seagen's earnings call?

Seagen will be holding an earnings conference call on Thursday, February 11th at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available.

How were Seagen's earnings last quarter?

Seagen Inc. (NASDAQ:SGEN) posted its quarterly earnings results on Thursday, October, 29th. The biotechnology company reported $3.50 EPS for the quarter, beating analysts' consensus estimates of ($0.08) by $3.58. The biotechnology company earned $1.06 billion during the quarter, compared to analyst estimates of $486.67 million. Seagen had a net margin of 25.34% and a trailing twelve-month return on equity of 20.46%. Seagen's revenue for the quarter was up 397.9% on a year-over-year basis. During the same quarter last year, the business earned ($0.55) earnings per share.
View Seagen's earnings history
.

What guidance has Seagen issued on next quarter's earnings?

Seagen updated its FY 2020 After-Hours earnings guidance on Thursday, October, 29th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $2.02-2.065 billion, compared to the consensus revenue estimate of $1.5 billion.

What price target have analysts set for SGEN?

17 equities research analysts have issued 1 year price targets for Seagen's shares. Their forecasts range from $124.00 to $254.00. On average, they anticipate Seagen's stock price to reach $185.71 in the next year. This suggests a possible upside of 14.2% from the stock's current price.
View analysts' price targets for Seagen
or view Wall Street analyst' top-rated stocks.

Who are some of Seagen's key competitors?

What other stocks do shareholders of Seagen own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Seagen investors own include NVIDIA (NVDA), AbbVie (ABBV), Advanced Micro Devices (AMD), Gilead Sciences (GILD), salesforce.com (CRM), QUALCOMM (QCOM), Tesla (TSLA), Micron Technology (MU), Netflix (NFLX) and Alibaba Group (BABA).

Who are Seagen's key executives?

Seagen's management team includes the following people:
  • Dr. Clay B. Siegall, Co-Founder, Chairman, Pres & CEO (Age 60, Pay $2.88M)
  • Mr. Todd E. Simpson, Chief Financial Officer (Age 60, Pay $1.11M)
  • Ms. Jean I. Liu, Gen. Counsel, Exec. VP of Legal Affairs & Corp. Sec. (Age 53, Pay $1M)
  • Dr. Roger D. Dansey M.D., Chief Medical Officer (Age 64, Pay $1.74M)
  • Dr. Vaughn B. Himes, Chief Technical Officer (Age 60)
  • Peggy Pinkston, VP of Investor Relations
  • Ms. Nancy Whiting B.Sc., Pharm.D., Exec. VP of Corp. Strategy, Alliances & Communications
  • Ms. Natasha A. Hernday, Exec. VP of Corp. Devel. (Age 49)
  • Mr. Matt Skelton, VP of Marketing
  • Mr. Christopher P. Pawlowicz, Exec. VP of HR

What is Seagen's stock symbol?

Seagen trades on the NASDAQ under the ticker symbol "SGEN."

Who are Seagen's major shareholders?

Seagen's stock is owned by many different institutional and retail investors. Top institutional investors include Candriam Luxembourg S.C.A. (0.28%), Frontier Capital Management Co. LLC (0.20%), Pinnacle Associates Ltd. (0.19%), Manning & Napier Group LLC (0.05%), Columbus Circle Investors (0.05%) and Rhenman & Partners Asset Management AB (0.04%). Company insiders that own Seagen stock include Bros Advisors Lp Baker, Charles R Romp, Clay B Siegall, Daniel G Welch, David W Gryska, Jean I Liu, Lip Bu Tan, Marc E Lippman, Roger D Dansey, Srinivas Akkaraju, Todd E Simpson and Vaughn B Himes.
View institutional ownership trends for Seagen
.

Which major investors are selling Seagen stock?

SGEN stock was sold by a variety of institutional investors in the last quarter, including Frontier Capital Management Co. LLC, Pinnacle Associates Ltd., Gateway Investment Advisers LLC, Pacer Advisors Inc., Rhenman & Partners Asset Management AB, Candriam Luxembourg S.C.A., Tributary Capital Management LLC, and Janney Montgomery Scott LLC. Company insiders that have sold Seagen company stock in the last year include Bros Advisors Lp Baker, Charles R Romp, Clay B Siegall, Daniel G Welch, David W Gryska, Jean I Liu, Marc E Lippman, Roger D Dansey, Todd E Simpson, and Vaughn B Himes.
View insider buying and selling activity for Seagen
or view top insider-selling stocks.

Which major investors are buying Seagen stock?

SGEN stock was acquired by a variety of institutional investors in the last quarter, including Manning & Napier Group LLC, Strs Ohio, Columbus Circle Investors, Nia Impact Advisors LLC, Highland Capital Management LLC, Louisiana State Employees Retirement System, Polianta Ltd, and XTX Markets LLC.
View insider buying and selling activity for Seagen
or or view top insider-buying stocks.

How do I buy shares of Seagen?

Shares of SGEN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Seagen's stock price today?

One share of SGEN stock can currently be purchased for approximately $162.58.

How big of a company is Seagen?

Seagen has a market capitalization of $29.41 billion and generates $916.71 million in revenue each year. The biotechnology company earns $-158,650,000.00 in net income (profit) each year or ($1.33) on an earnings per share basis. Seagen employs 1,605 workers across the globe.

What is Seagen's official website?

The official website for Seagen is www.seattlegenetics.com.

How can I contact Seagen?

Seagen's mailing address is 21823 30TH DRIVE SE SUITE, BOTHELL WA, 98021. The biotechnology company can be reached via phone at 425-527-4000 or via email at [email protected]

This page was last updated on 1/27/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.